REFERENCES
2. Lublin FD, Reingold SC, Cohen JA, Cutter GR, Sørensen PS, et al. Defining the clinical course of multiple sclerosis. Neurology 2014;83:278-86.
4. Mori M, Kuwabara S, Paul F. Worldwide prevalence of neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:555-6.
6. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004;364:2106-12.
7. Jarius S, Wildemann B, Paul F. Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 2014;176:149-64.
8. Takeshita Y, Obermeier B, Cotleur AC, Spampinato SF, Shimizu F, et al. Effects of neuromyelitis optica-IgG at the blood-brain barrier in vitro. Neurol Neuroimmunol Neuroinflamm 2016;4:e311.
10. Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyeliis. Lancet Neurol 2007;6:805-15.
11. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015;85:177-89.
12. Kawachi I, Lassmann H. Neurodegeneration in multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatry 2017;88:137-45.
13. Dargahi N, Katsara M, Tselios T, Androutsou ME, de Courten M, et al. Multiple sclerosis: immunopathology and treatment update. Brain Sci 2017;7:E78.
14. Lovett-Racke AE, Yang Y, Racke MK. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis? Biochim Biophys Acta 2011;1812:246-51.
15. Garg N, Smith TW. An update on immunopathogenesis, diagnosis, and treatment of multiple sclerosis. Brain Behav 2015;5:e00362.
16. Lehmann PV, Rottlaender A, Kuerten S. The autoimmune pathogenesis of multiple sclerosis. Pharmazie 2015;70:5-11.
17. Van Kaer L, Wu L, Parekh VV. Natural killer t cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Immunology 2015;146:1-10.
18. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545-58.
19. von Büdingen HC, Palanichamy A, Lehmann-Horn K, Michel BA, Zamvil SS, et al. Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets. Eur Neurol 2015;73:238-46.
20. Bennett JL, O’Connor KC, Bar-Or A, Zamvil SS, Hemmer B, et al. B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015;2:e104.
21. Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008;5:22.
22. Hertwig L, Pache F, Romero-Suarez S, Stürner KH, Borisow N, et al. Distinct functionality of neutrophils in multiple sclerosis and neuromyelitis optica. Mult Scler 2016;22:160-73.
23. Borisow N, Mori M, Kuwabara S, Scheel M, Paul F, et al. Diagnosis and treatment of NMO spectrum disorder and MOG-encephalomyelitis. Front Neurol 2018;9:888.
24. Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord 2018;25:66-72.
25. Zamvil SS, Slavin AJ. Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflamm 2015;2:e62.
26. Pelt ED, Wong YY, Ketelslegers IA, Hamann D, Hintzen RQ, et al. Neuromyelitis optica spectrum disorders: comparison of clinica land magnetic resonanceimaging characteristics of AQP4-IgG versus MOG- IgG seropositive cases in the Netherlands. EurJNeurol 2016;23:580-7.
27. Vourc’h P, Andres C. Oligodendrocyte myelin glycoprotein (OMgp): evolution, structure and function. Brain Res Brain Res Rev 2004;45:115-24.
28. Jarius S, Ruprecht K, Kleiter I, Borisow N, Asgari N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, longterm course, association with AQP4-IgG, and origin. J Neuroinflamm 2016;13:279.
29. Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011;306:82-90.
30. Mealy MA, Kim SH, Schmidt F, López R, Jimenez Arango JA, et al. Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. Mult Scler 2018;24:1737-42.
31. Jarius S, Ruprecht K, Stellmann JP, Huss A, Ayzenberg I, et al. MOG-IgG in primary and secondary chronic progressive multiple sclerosis: a multicenter study of 200 patients and review of the literature. J Neuroinflamm 2018;15:88.
32. Diebold M, Derfuss T. Immunological treatment of multiple sclerosis. Semin Hematol 2016;53:S54-7.
33. Kleiter I, Gold R. Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics 2016;13:70-83.
34. Inglese M, Petracca M. Therapeutic strategies in multiple sclerosis: a focus on neuroprotection and repair and relevance to schizophrenia. Schizophr Res 2015;161:94-101.
35. Morrow SA, Metz LM, Kremenchutzky M. High dose oral steroids commonly used to treat relapses in canadian ms clinics. Can J Neurol Sci 2009;36:213-5.
36. Compston DA, Milligan NM, Hughes PJ, Gibbs J, McBroom V, et al. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 2. Laboratory results. J Neurol Neurosurg Psychiatry 1987;50:517-22.
37. Barkhof F, Hommes OR, Scheltens P, Valk J. Quantitative MRI changes in gadolinium-DTPA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991;41:1219-22.
38. Bonnan M, Cabre P. Plasma exchange in severe attacks of neuromyelitis optica. Mult Scler Int 2012;2012:787630.
39. Trebst C, Bronzlik P, Kielstein JT, Schmidt BM, Stangel M, et al. Immunoadsorption therapy for steroid-unresponsive relapses in patients with multiple sclerosis. Blood Purif 2012;33:1-6.
40. Koziolek MJ, Tampe D, Bahr M, Dihazi H, Jung K, et al. Immunoadsorption therapy in patients with multiple sclerosis with steroid-refractory optical neuritis. J Neuroinflammation 2012;9:80.
41. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, et al. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 2014;261:1-16.
42. Elovaara I, Kuusisto H, Wu X, Rinta S, Dastidar P, et al. Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse. Clin Neuropharmacol 2011;34:84-9.
43. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-4.
45. Wingerchuk DM. Neuromyelitis optica: potential roles for intravenous immunoglobulin. J Clin Immunol 2013;33:S33-7.
46. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8.
47. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler 2005;11:425-32.
48. Martinelli V, Roca MA, Annovazzi P, Pulizzi A, Rodegher M, et al. A short-term randomized MRI study of high dose oral vs intravenous methylprednisolone in MS. Neurology 2009;73:1842-8.
49. Burton JM, O’Connor PW, Hohol M, Beyene J. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis. Cochrane Database Syst Rev 2009;8:CD006921.
50. Ramo-Tello C, Grau-López L, Tintoré M, Rovira A, Ramió i Torrenta L, et al. A randomized clinical trial of oral versus intravenous methylprednisolone for relapse of MS. Mult Scler 2014;20:717-25.
51. Le Page E, Veillard D, Laplaud DA, Hamonic S, Wardi R, et al. Oral versus intravenous high-dose methylprenisolone for treatment of relapses in patients with multiple sclerosis (COPOUSEP): a randomized, controlled, double-blind, non-inferiority trial. Lancet 2015;386:974-81.
52. Sellebjerg F, Barnes D, Filippini G, Midgard R, Montalban X, et al. EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. Eur J of Neurol 2005;12:939-46.
53. Perumal JS, Caon C, Hreha S, Zabad R, Tselis A, et al. Oral prednisone taper following intravenous steroids fails to improve disability or recovery from relapses in multiple sclerosis. Eur J Neurol 2008;15:677-80.
54. Levic Z, Micic D, Nikolic J, Stojisavljević N, Sokić D, et al. Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. J Endocrinol Invest 1996;19:30-4.
55. Wenning GK, Wietholter H, Schnauder G, Muller PH, Kanduth S, et al. Recovery of the hypothalamic-pituitary-adrenal axis from suppression by short-term, high-dose intravenous prednisolone therapy in patients with MS. Acta Neurol Scand 1994;89:270-3.
56. Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler 2007;13:968-74.
57. Ramanathan S, Mohammad S, Tantsis E, Nguyen TK, Merheb V, et al. Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. J Neurol Neurosurg Psychiatry 2018;89:127-37.
58. Sato D, Callegaro D, Lana-Peixoto MA, Fujihara K; Brazilian Committee for Treatment and Research in Multiple Sclerosis. Treatment of neuromyelitis optica: an evidence based review. Arq Neuropsiquiatr 2012;70:59-66.
59. Palace J, Leite MI, Jacob A. A practical guide to the treatment of neuromyelitis optica. Pract Neurol 2012;12:209-14.
60. Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999;53:1107-14.
61. Bichuetti DB, Oliveira EM, Souza NA, Tintoré M, Gabbai AA. Patients with neuromyelitis optica have a more severe disease than patients with relapsing remitting multiple sclerosis, including higher risk of dying of a demyelinating disease. Arq Neuropsiquiatr 2013;71:275-9.
62. Yamasaki R, Matsushita T, Fukazawa T, Yokoyama K, Fujihara K, et al. Efficacy of intravenous methylprednisolone pulse therapy in patients with multiple sclerosis and neuromyelitis optica. Mult Scler 2016;22:1337-48.
65. McDaneld LM, Fields JD, Bourdette DN, Bhardwaj A. Immunomodulatory therapies in neurologic critical care. Neurocrit Care 2010;12:132-43.
66. Lipphardt M, Mühlhausen J, Kitze B, Heigl F, Mauch E, et al. Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.21686. [Last accessed on 23 Apr 2019].
67. Correia I, Ribeiro JJ, Isidoro L, Batista S, Nunes C, et al. Plasma exchange in severe acute relapses of multiple sclerosis - results from a portuguese cohort. Mult Scler Relat Disord 2018;19:148-52.
68. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, et al. Apheresis therapies for NMOSD attacks: a retrospective study of 207 therapeutic interventions. Neurol Neuroimmunol Neuroinflamm 2018;5:e504.
69. Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007;13:128-32.
70. Merle H, Olindo S, Jeannin S, Valentino R, Mehdaoui H, et al. Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica. Arch Ophthalmol 2012;130:858-62.
71. Bonnan M, Valentino R, Debeugny S, Merle H, Fergé JL, et al. Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders. J Neurol Neurosurg Psychiatry 2018;89:346-51.
72. Kleiter I, Gahlen A, Borisow N, Fischer K, Wernecke KD, et al. Neuromyelitis optica: Evaluation of 871 attacks and 1,153 treatment courses. Ann Neurol 2016;79:206-16.
73. Schwab, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG modulate the immune system? Nat Rev Immunol 2013;13:176-89.
74. Elsone L, Panicker J, Mutch K, Boggild M, Appleton R, et al. Role of intravenous immunoglobulin in the treatment of acute relapses of neuromyelitis optica: experience in 10 patients. Mult Scler 2014;20:501-4.
75. Sorensen PS, Haas J, Sellebjerg F, Olsson T, Ravnborg M, et al. IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. Neurology 2004;63:2028-33.
76. Visser LH, Beekman R, Tijssen CC, Uitdehaag BM, Lee ML, et al. A randomized, double-blind, place-controlled pilot study of IV immune globulins in combination with IV methylprednisolone in the treatment of relapses in patients with MS. Mult Scler 2004;10:89-91.
77. Olyaeemanesh A, Rahmani M, Goudarzi R, Rahimdel A. Safety and effectiveness assessment of intravenous immunoglobulin in the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. Med J Islam Repub Iran 2016;30:336.
78. Magraner MJ, Coret F, Casanova B. The effect of intravenous immunoglobulin on neuromyelitis optica. Neurologia 2013;28:65-72.
79. Viswanathan S, Wong AH, Quek AM, Yuki N. Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica. J Neuroimmunol 2015;282:92-6.
80. Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern Med 2007;46:1671-2.
81. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545-58.
82. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, et al. ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis. Mult Scler 2018;24:96-120.
83. Rae-Grant A. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2019;92:110-1.
84. Sahraian MA, Moghadasi AN, Azimi AR, Asgari N, et al. Diagnosis and management of Neuromyelitis Optica Spectrum Disorder (NMOSD) in Iran: a consensus guideline and recommendations. Mult Scler Relat Disord 2017;18:144-51.
85. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010;17:1019-32.
86. Trebst C, Berthele A, Jarius S, Kümpfel T, Schippling S, et al. Diagnosis and treatment of neuromyelitis optical consensus recommendations of the Neuromyelitis Optica Study Group. Nervenarzt 2011;82:768-77.
87. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
88. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:662-7.
89. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
90. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-8.
91. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, et al. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-63.
92. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
93. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, et al. Pegylated interferon beta-1a for relapsing remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double- blind study. Lancet Neurol 2014;13:657-65.
94. Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, et al. Interferon beta-1b in secondary progressive multiple sclerosis-outline of the clinical trial. Mult Scler 1995;1:S51-4.
95. Kuhle J, Hardmeier M, Disanto G, Gugleta K2, Ecsedi M, et al. A 10-year follow-up of the European multicenter trial of interferonβ-1b in secondary-progressive multiple sclerosis. Mult Scler 2016;22:533-43.
96. Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, et al. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2004;75:706-10.
97. ITur C, Montalban X, Tintoré M, Nos C, Río J, et al. Interferonβ-1b for the treatment of primary progressive multiple sclerosis: five-year clinical trial follow-up. Arch Neurol 2011;68:1421-7.
98. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, et al. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009;15:1195-205.
99. Hegen H, Auer M, Deisenhammer F. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Expert Opin Drug Metab Toxicol 2015;11:1803-19.
101. Furber KL, Van Agten M, Evans C, Haddadi A, Doucette JR, et al. Advances in the treatment of relapsing-remitting multiple sclerosis: the role of pegylated interferonβ-1a. Degener Neurol Neuromuscul Dis 2017;7:47-60.
102. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R. Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action. CNS Drugs 2011;25:401-14.
103. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12:543-53.
104. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology 2010;74:S25-30.
105. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.1995. Neurology 2001;57:S16-24.
106. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology 1998;50:701-8.
107. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-66.
108. Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. J Neurol Sci 2000;181:33-7.
109. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, et al. Three times weekly glatiramer acetate in relapsing remitting multiple sclerosis. Ann Neurol 2013;73:705-13.
110. Wolinsky JS, Narayana PA, O’ Connor P, Coyle PK, Ford C, et al. Glatiramer acetate in primary progressive multiple sclerosis: results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
111. Millefiorini E, Gasperini C, Pozzilli C, D’Andrea F, Bastianello S, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-9.
112. Le Page E, Leray E, Taurin G, Coustans M, Chaperon J, et al. Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients. J Neurol Neurosurg Psychiatry 2008;79:52-6.
113. Rivera VM, Jeffery DR, Weinstock-Guttman B, Bock D, Dangond F. Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study. BMC Neurol 2013;13:80.
114. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-25.
115. van de Wyngaert FA, Beguin C, D’Hooghe MB, Dooms G, Lissoir F, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101:210-6.
116. Mehling M, Brinkmann V, Antel J, Bar-Or A, Goebels N, et al. FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology 2008;71:1261-7.
117. Miron VE, Ludwin SK, Darlington PJ, Jarjour AA, Soliven B, et al. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol 2010;176:2682-94.
118. Miron VE, Schubart A, Antel JP. Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci 2008;274:13-7.
119. Kappos L, Radue EW, O’ Connor P, Polman C, Hohlfeld R, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401.
120. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56.
121. Khatri B, Barkhof F, Comi G, Hartung HP, Kappos L, et al. Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol 2011;10:520-9.
122. Saida T, Kikuchi S, Itoyama Y, Hao Q, Kurosawa T, et al. A randomized, controlled trial of fingolimod (FTY720) in Japanese patients with multiple sclerosis. Mult Scler 2012;18:1269-77.
123. Ordoñez-Boschetti L, Rey R, Cruz A, Sinha A, Reynolds T, et al. Safety and tolerability of fingolimod in Latin American patients with relapsing-remitting multiple sclerosis: the open-label FIRST LATAM study. Adv Ther 2015;32:626-35.
124. Cohen JA, Khatri B, Barkhof F, Comi G, Hartung HP, et al. Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomized TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016;87:468-75.
125. Lublin F, Miller DH, Freedman MS, Cree BAC, Wolinsky JS, et al. Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet 2016;387:1075-84.
126. Papadopoulou A, Kappos L, Sprenger T. Teriflunomide for oral therapy in multiple sclerosis. Expert Rev Clin Pharmacol 2012;5:617-28.
127. Martin R, Sospedra M, Rosito M, Engelhardt B. Current multiple sclerosis treatments have improved our understanding of MS autoimmune pathogenesis. Eur J Immunol 2016;46:2078-90.
128. Confavreux C, O’ Connor P, Comi G, Freedman MS, Miller AE, et al. Oral teriflunomide for patients with relapsing multiple scle-rosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:247-56.
129. O’ Connor P, Wolinsky JS, Confavreux C, Comi G, Kappos L, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365:1293-303.
130. O’ Connor P, Comi G, Freedman MS, Miller AE, Kappos L, et al. Long-term safety and efficacy of teriflunomide: nine-year follow-up of the randomized TEMSO study. Neurology 2016;86:920-30.
131. Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, et al. Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. Mult Scler 2014;20:705-16.
132. Salmen A, Gold R. Mode of action and clinical studies with fumarates in multiple sclerosis. Exp Neurol 2014;262:52-6.
133. Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, et al. Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety. Expert Rev Neurother 2015;15:339-46.
134. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367:1098-107.
135. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367:1087-97.
136. Gold R, Arnold DL, Bar-Or A, Hutchinson M, Kappos L, et al. Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: interim analysis of ENDORSE, a randomized extension study. Mult Scler 2017;23:253-65.
137. Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992;356:63-6.
138. Derfuss T, Kuhle J, Lindberg R, Kappos L. Natalizumab therapy for multiple sclerosis. Semin Neurol 2013;33:26-36.
139. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354:911-23.
140. Polman CH, O’ Connor PW, Havrdova E, Hutchinson M, Kappos L, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354:899-910.
141. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: resultsfrom a multi-center study in German speaking countries. Eur J Neurol 2010;17:31-7.
142. Outteryck O, Ongagna JC, Zéphir H, Fleury MC, Lacour A, et al. Demographic and clinic characteristics of French patients treated with natalizumab in clinical practice. J Neurol 2010;257:207-11.
143. Putzki N, Yaldizli O, Mäurer M, Cursiefen S, Kuckert S, et al. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multicenter study in German speaking countries. Eur J Neurol 2010;17:31-7.
144. Butzkueven H, Kappos L, Pellegrini F, Trojano M, Wiendl H, et al. Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results. J Neurol Neurosurg Psychiatry 2014;85:1190-7.
145. Saida T, Kira JI, Kishida S, Yamamura T, Sudo Y, et al. Efficacy, safety, and pharmacokinetics of natalizumab in Japanese multiple sclerosis patients: a double-blind, randomized controlled trial and open-label pharmacokinetic study. Mult Scler Relat Disord 2017;11:25-31.
146. Cadavid D, Jurgensen S, Lee S. Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis. PLoS One 2013;8:e53297.
147. Ruck T, Bittner S, Wiendl H, Meuth SG. Alemtuzumab in multiple sclerosis: mechanism of action and beyond. Int J Mol Sci 2015;16:16414-39.
148. Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39.
149. Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380:1819-28.
150. Tuohy O, Costelloe L, Hill-Cawthorne G, Bjornson I, Harding K, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015;86:208-15.
151. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376:209-20.
152. Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378:1779-87.
153. Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, et al. Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 2017;376:221-34.
154. Giovannoni G, Comi G, Cook S, Rammohan K, Rieckmann P, et al. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. N Engl J Med 2010;362:416-26.
155. Stelmasiak Z, Solski J, Nowicki J, Jakubowska B, Ryba M, et al. Effect of parenteral cladribine on relapse rates in patients with relapsing forms of multiple sclerosis: results of a 2-year, double-blind, placebo-controlled, crossover study. Mult Scler 2009;15:767-70.
156. Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, et al. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet 2018;391:1263-73.
157. Kappos L, Li DK, Stüve O, Hartung HP, Freedman MS, et al. Safety and efficacy of Siponimod (BAF312) in patients with relapsing-remitting multiple sclerosis: dose-blinded, randomized extension of the phase 2 BOLD study. JAMA Neurol 2016;73:1089-98.
158. Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol 2013;12:756-67.
159. Nikoo Z, Badihian S, Shaygannejad V, Asgari N, Ashtari F, et al. Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. J Neurol 2017;264:2003-9.
160. Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008;63:395-400.
161. Naismith RT, Piccio L, Lyons JA, Lauber J, Tutlam NT, et al. Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trial. Neurology 2010;74:1860-7.
162. Hawker K, O’ Connor P, Freedman MS, Calabresi PA, Antel J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66:460-71.
163. Huang TL, Lin KH, Wang JK, Tsai RK. Treatment strategies for neuromyelitis optica. Ci Ji Yi Xue Za Zhi 2018;30:204-8.
164. Mandler RN, Ahmed W, Dencoff JE. Devic’s neuromyelitis optica: a prospective study of seven patients treated with prednisone and azathioprine. Neurology 1998;51:1219-20.
165. Bichuetti DB, Perin MMM, Souza NA, Oliveira EML. Treating neuromyelitis optica with azathioprine: 20-year clinical practice. Mult Scler 2018; doi: 10.1177/1352458518776584.
166. Qiu W, Kermode AG, Li R, Dai Y, Wang Y, et al. Azathioprine plus corticosteroid treatment in Chinese patients with neuromyelitis optica. J Clin Neurosci 2015;22:1178-82.
167. Massacesi L, Tramacere I, Amoroso S, Battaglia MA, Benedetti MD, et al. Azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomized non-inferiority trial. PLoS One 2014;9:e113371.
168. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, et al. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004;107:63-8.
169. Torres J, Pruitt A, Balcer L, Galetta S, Markowitz C, et al. Analysis of the treatment of neuromyelitis optica. J Neurol Sci 2015;351:31-5.
170. Huh SY, Kim SH, Hyun JW, Joung AR, Park MS, et al. Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 2014;71:1372-8.
171. Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009;66:1128-33.
172. Huang Q, Wang J, Zhou Y, Yang H, Wang Z, et al. Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China. Front Immunol 2018;9:2066.
173. Bruck W, Stadelmann C. Inflammation and degeneration in multiple sclerosis. J Neurol Sci 2003;24:S265-7.
174. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F. Early mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007;78:198-200.
175. Stettner M, Gross CC, Mausberg AK, Pul R, Junker A, et al. A fatal case of daclizumab-induced liver failure in a patient with MS. Neurol Neuroimmunol Neuroinflamm 2019;6:e539.
176. Luessi F, Engel S, Spreer A, Bittner S, Zipp F. GFAPα IgG-associated encephalitis upon daclizumab treatment of MS. Neurol Neuroimmunol Neuroinflamm 2018;5:e481.
177. Baharnoori M, Lyons J, Dastagir A, Koralnik I, Stankiewicz JM. Nonfatal PML in a patient with multiple sclerosis treated with dimethyl fumarate. Neurol Neuroimmunol Neuroinflamm 2016;3:e274.
178. Berger JR, Cree BA, Greenberg B, Hemmer B, Ward BJ, et al. Progressive multifocal leukoencephalopathy after fingolimod treatment. Neurology 2019;92:151.
179. Maillart E, Vidal JS, Brassat D, Stankoff B, Fromont A, et al. Natalizumab-PML survivors with subsequent MS treatment: clinico-radiologic outcome. Neurol Neuroimmunol Neuroinflamm 2017;4:e346.
180. Meira M, Sievers C, Hoffmann F, Haghikia A, Rasenack M, et al. Natalizumab-induced POU2AF1/Spi-B upregulation: a possible route for PML development. Neurol Neuroimmunol Neuroinflamm 2016;3:e223.
181. Major EO, Nath A. A link between long-term natalizumab dosing in MS and PML: putting the puzzle together. Neurol Neuroimmunol Neuroinflamm 2016;3:e235.
182. Bsteh G, Auer M, Iglseder S, Walchhofer LM, Langenscheidt D, et al. Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc. Neurol Neuroimmunol Neuroinflamm 2017;4:e323.
183. Hodecker SC, Stürner KH, Becker V, Elias-Hamp B, Holst B, et al. Maraviroc as possible treatment for PML-IRIS in natalizumab-treated patients with MS. Neurol Neuroimmunol Neuroinflamm 2017;4:e325.
184. Yang Y, Wang CJ, Wang BJ, Zeng ZL, Guo SG. Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. J Neurol Sci 2018;385:192-7.
185. Etemadifar M, Salari M, Mirmosayyeb O, Serati M, Nikkhah R, et al. Efficacy and safety of rituximab in neuromyelitis optica: review of evidence. J Res Med Sci 2017;22:18.
186. Rommer PS, Dörner T, Freivogel K, Haas J, Kieseier BC, et al. Safety and clinical outcomes of rituximab treatment in patients with multiple sclerosis and neuromyelitis optica: experience from a national online registry (GRAID). J Neuroimmune Pharmacol 2016;11:1-8.
187. Damato V, Evoli A, Iorio R. Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis. JAMA Neurol 2016;73:1342-8.
188. Marcinnò A, Marnetto F, Valentino P, Martire S, Balbo A, et al. Rituximab-induced hypogammaglobulinemia in patients with neuromyelitis optica spectrum disorders. Neurol Neuroimmunol Neuroinflamm 2018;5:e498.
189. Ellwardt E, Ellwardt L, Bittner S, Zipp F. Monitoring B-cell repopulation after depletion therapy in neurologic patients. Neurol Neuroimmunol Neuroinflamm 2018;5:e463.
190. Kowarik MC, Hoshi M, Hemmer B, Berthele A. Failure of alemtuzumab as a rescue in a NMOSD patient treated with rituximab. Neurol Neuroimmunol Neuroinflamm 2016;3:e208.
191. Gahlen A, Trampe AK, Haupeltshofer S, et al. Aquaporin-4 antibodies in patients treated with natalizumab for suspected MS. Neurol Neuroimmunol Neuroinflamm 2017;4:e363.
192. Azzopardi L, Cox AL, McCarthy CL, Jones JL, Coles AJ. Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series. J Neurol 2016;263:25-9.
193. Trebst C, Jarius S, Berthele A, Paul F, Schippling S. Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the neuromyelitis optica study group (NEMOS). J Neurol 2014;261:1-16.
194. Popiel M, Psujek M, Bartosik-Psujek H. Severe disease exacerbation in a patient with neuromyelitis optica spectrum disorder during treatment with dimethyl fumarate. Mult Scler Relat Disord 2018;26:204-6.
195. Stellmann JP, Krumbholz M, Friede T, Gahlen A, Borisow N, et al. Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response. J Neurol Neurosurg Psychiatry 2017;88:639-47.
196. Ayzenberg I, Schöllhammer J, Hoepner R, Hellwig K, Ringelstein M, et al. Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study. J Neurol 2016;263:575-82.
197. Jarius S, Ruprecht K, Kleiter, Borisow N, Asgari N, et al. MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016;13:280.
198. Jurynczyk M, Messina S, Woodhall MR, Raza N, Everett R, et al. Clinical presentation and prognosis in MOG-antibody disease: a UK study. Brain 2017;140:3128-38.
199. Zipoli V, Portaccio E, Hakiki B, Siracusa G, Sorbi S, et al. Intravenous mitoxantrone and cyclophosphamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety. J Neurol Sci 2008;266:25-30.
200. Brochet B, Deloire MS, Perez P, Loock T, Baschet L, et al. Double-blind controlled randomized trial of cyclophosphamide versus methylprednisolone in secondary progressive multiple sclerosis. PLoS One 2017;12:e0168834.
201. Jacques F, Gaboury I, Christie S, Grand’maison F. Combination therapy of interferon Beta-1b and tacrolimus: a pilot safety study. Mult Scler Int 2012;2012:935921.
